Insiders Trades
Teladoc Health, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 17 Nov 2025.
Teladoc Health, Inc.: what insiders have been doing
This page follows insider dealings at Teladoc Health, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Lewisville, United States. The group dates from 2002. Over the twelve months to 18 October 2026, the company's managers filed 69 filings, from 13 insiders.
Open-market activity splits into 1 purchase totalling €60k and 16 sales totalling €424k; 1 insider sit on the buying side and 6 insiders on the selling side. The amount is not disclosed for 3 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Those buying include 1 senior executive. One trade stands out by size: a sale of €100k from Divita Charles III, disclosed on 3 September 2026, or 0.010% of market capitalisation.
The last purchase on record was published on 17 November 2025, which is 335 days ago. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 69 filings here. Over the whole record (from 2016), the tally stands at 4 purchases and 83 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 2.53 bn USD and net income of -200.3 m USD.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
343
Thresholds
n/a
Buy Volume
€161,727
4 ops. · all time
Sell Volume
€12M
83 ops. · all time
Who traded when
BuySaleJoseph Ronald Catapano5 sales
Kelly Bliss5 sales
Charles Divita III3 sales
Fernando M. Rodrigues2 sales
Adam C. Vandervoort1 sale
Carlos Nueno1 sale
+1 other insider
Since the insiders bought
- -34.9%Entry US$7.00 · Close at T+90 US$4.56
- -5.2%Entry US$7.15 · Close at T+365 US$6.78
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Teladoc Health, Inc. Hold (neutral), based on 17 analysts. Average price target: US$7.59.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 16,579 of 24,148 companies
39.3
score / 100
Value46
Quality32
FCF yld13%
Earn yld-19%
EV/EBITDA13.0x
ROE-13%
Gross mgn70%
Net mgn-7.9%
Debt/EBITDA6.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$5.81
Analyst consensus
17 analystsHold
US$5.50Target US$7.59(+31%)US$10.50
Income statement
RevenueUS$2.5B
Gross profitUS$1.8B70% margin
EBITDAUS$160.6M6% margin
Net income-US$200.3M-7.1% margin
Valuation
PER (forward)-8.0x
P/Book0.8x
Beta2.14
Balance sheet & cash
Market capUS$1.1B
Total debtUS$1B
Free Cash FlowUS$137.3M
Debt / Equity79%
Profitability & ownership
ROE-13.0%
ROA-3.2%
% insiders0.7%
% institutions87.8%
Last declaration on 5 October 2026
Declarations343 total
2,083 sharesCommon StockSEC:0001714468-26-000014:0
655 shares@ US$5.6530.0004% mcap22.2% of flowCommon StockSEC:0001714468-26-000014:1
3,642 sharesCommon StockSEC:0001347535-26-000011:0
39,160 sharesCommon StockSEC:0001347535-26-000011:1
17,805 shares@ US$6.1040.0096% mcap18.0% of flowCommon StockSEC:0001347535-26-000011:2
17,805 shares@ US$6.10410.0096% mcap18.0% of flowCommonSEC144:0001959173-26-006894
4,859 sharesCommon StockSEC:0002036989-26-000014:0
9,152 sharesCommon StockSEC:0002036989-26-000014:1
7,357 shares@ US$6.3010.0041% mcap20.0% of flowCommon StockSEC:0002036989-26-000014:3
1,300 sharesCommon StockSEC:0002036989-26-000014:2
4,556 sharesCommon StockSEC:0002037711-26-000006:0
5,492 sharesCommon StockSEC:0002037547-26-000008:0
5,350 sharesCommon StockSEC:0001375088-26-000006:0
9,152 sharesCommon StockSEC:0001375088-26-000006:1
426 sharesCommon StockSEC:0001375088-26-000006:2
8,717 sharesCommon StockSEC:0002037711-26-000006:1
6,200 shares@ US$6.3010.0034% mcap45.3% of flowCommon StockSEC:0002037711-26-000006:2
1,042 sharesCommon StockSEC:0002037547-26-000008:1
8,717 sharesCommon StockSEC:0002037547-26-000008:2
5,439 shares@ US$6.3010.0030% mcap13.8% of flowCommon StockSEC:0002037547-26-000008:3
7,573 shares@ US$6.3010.0042% mcap3.5% of flowCommon StockSEC:0001375088-26-000006:3
9,812 shares@ US$6.510.0056% mcap25.8% of flowCommonSEC144:0001959173-26-006692
39 sharesCommon StockSEC:0001714468-26-000012:1
1,966 sharesCommon StockSEC:0001347535-26-000009:1
42,277 sharesCommon StockSEC:0001347535-26-000009:0
25 of 343 declarations
About Teladoc Health, Inc.
Teladoc Health, Inc. (NYSE: TDOC) is a US-listed virtual healthcare company headquartered in Purchase, New York, United States. Founded in 2002, Teladoc was an early mover in large-scale telemedicine and has evolved from a pure teleconsultation provider into a broader whole-person virtual care platform. For European investors, the key takeaway is that Teladoc sits at the intersection of healthcare services and technology-enabled care delivery, with a model primarily driven by enterprise relationships rather than direct consumer demand alone.
The company’s business is organized around two reportable segments. Integrated Care includes virtual medical visits, expert medical opinions, chronic care programs, mental health offerings, and preventive care solutions delivered through employers, health plans, health systems, and other institutions. BetterHelp is the company’s direct-to-consumer mental health platform, connecting users with licensed therapists through an online subscription model. Teladoc also offers licensable platform services, analytics, and related digital health capabilities, which broaden its role across the patient journey from initial access to follow-up care.
Read moreShow less
Teladoc’s history is closely tied to the rise of telehealth in the United States. Over time, the company expanded through acquisitions and brand integration, adding assets such as BetterHelp and other specialist virtual-care capabilities to deepen its product suite. That consolidation helped Teladoc build a globally recognized brand and a sizable enterprise footprint. The company has historically emphasized its international reach and its ability to serve a large and diverse customer base across multiple healthcare channels.
From a competitive standpoint, Teladoc remains one of the best-known names in virtual care, but the market has become more demanding. Post-pandemic normalization, pricing pressure, and higher customer-acquisition costs have weighed on growth and profitability. In its full-year 2024 results, Teladoc reported revenue of $2.57 billion, down slightly year over year, alongside a significant net loss, while adjusted EBITDA and cash generation remained positive. The Integrated Care segment showed relative resilience, whereas BetterHelp continued to face a challenging operating environment.
Recent strategic developments are important for investors. In early 2025, Teladoc announced an agreement to acquire Catapult Health, a move intended to strengthen preventive care and chronic-care capabilities and expand at-home testing. Management has also highlighted cost-reduction actions, organizational streamlining, and efforts to stabilize BetterHelp while accelerating international growth. These steps suggest a stronger focus on efficiency and on improving the quality of growth rather than pursuing volume at any cost.
In short, Teladoc Health is a NYSE-listed United States healthcare platform with meaningful scale, recognized branding, and a diversified virtual-care offering. The investment case depends on whether the company can convert its broad market position into more durable profitability and sustained segment-level growth, especially as virtual care competition intensifies and reimbursement dynamics continue to evolve.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
